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sided medical tape and used to determine each of the three test angles.
Participants were ﬁrst shown one of the angles, which was held for a few
seconds, then were asked to close their eyes and attempt to reproduce the
angle; this was repeated for all three test angles. We also repeated these
assessments at 24 and 48 weeks to test durability of response. The mean
error (absolute angle error) between the actual and replicated angles was
calculated for each of the three test angles. The Tai Chi and control groups
were compared by intention-to-treat using t-tests.
Results: The participants had a mean age of 65y (SD 7.8), mean disease
duration 10y (SD 7.6), mean BMI 30.0 kg/m2 (SD 4.8), and median K/L
grade 4; 75% were female, 70% were white. There were no signiﬁcant
differences at baseline in demographics, radiographic score, and outcome
measures. Attendance rate was 85% in the Tai Chi versus 89% in the
attention control. Participants in the Tai Chi arm exhibited signiﬁcantly
improved proprioception at 30 degrees, but not at 45 and 60 degrees, at
12 weeks (Table 1). Patients who continued Tai Chi practice after 12 weeks
also reported no signiﬁcant improvements in knee proprioception at 24
and 48 weeks.
Conclusion: We were not able to demonstrate in this pilot study that
Tai Chi is beneﬁcial for knee proprioception in people with severe KOA.
Potential confounders of the test including baseline characteristics, knee
pain severity, effusion and function, modiﬁed Tai Chi style, changes in joint
position and body weight, small sample size may limit data interpretation
and evaluation of the results. Standardized and reproducible measures for
knee proprioception should be explored in the future research.
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Purpose: In previous studies, naproxcinod, a novel cyclooxygenase inhibit-
ing nitric oxide donator (CINOD), has shown eﬃcacy similar to naproxen
in the treatment of the signs and symptoms of hip and knee osteoarthritis
(OA), but with effects on blood pressure (BP) similar to placebo. The
objective of this analysis is to determine if nitric oxide donation from
naproxcinod contributes to any difference in change in joint space width in
the tibio-femoral joint over one year compared to naproxen.
Methods: Data were analyzed from a 53-week, randomized, double-blind,
parallel-group clinical trial of 1020 patients with idiopathic knee OA who
were randomized to naproxcinod 750 mg, naproxcinod 375 mg, naproxen
500 mg or placebo (all bid) for 13 weeks; patients who had received
placebo were then re-randomized to naproxcinod either 750 mg or 375 mg
bid. Weight-bearing posterior-anterior (PA) radiographs were obtained in
the semiﬂexed position with a standard protocol by radiology technicians
using the SynaFlexer™ positioning device at baseline (between 4 and
10 days prior to randomization) and after 52 weeks in patients who
completed the study. All images (either hard copy or digital) were sent to
Synarc Inc. (San Francisco, CA) for quality assessment. A single trained and
certiﬁed radiologist measured minimum joint space width (JSW) using a
semiautomatic computer program on digitized images that were paired by
subject but randomized and blinded to time sequence. Mean (SD) change
in minimum JSW by compartment in the index knee was calculated for
each treatment group. No statistical comparisons were performed of this
exploratory safety endpoint.
Results: A total of 1020 patients with idiopathic knee OA were enrolled in
the study and randomized to one of the four treatment groups: mean (SD)
Table 1
All in Millimeters Naproxcinod 750 Naproxcinod 375 Naproxen 500
Medial compartment
Mean change (SD) 0.130 (0.92) -0.064 (0.812) 0.118 (1.18)
Median change (min, max) 0.00 (-2.06, 3.79) -0.01 (-4.22, 1.98) 0.00 (-3.73, 6.87)
Lateral compartment
Mean change (SD) -0.109 (1.23) -0.145 (0.98) -0.153 (1.22)
Median change (min, max) -0.06 (-5.58, 3.50) -0.02 (-3.66, 2.00) -0.08 (-6.15, 3.24)
age 59.8 (9.8) years, 709 (71%) women, 789 (79%) white, mean BMI 33.8
kg/m2. A total of 391 subjects completed 52 weeks on study medication
and had paired knee x-rays that were read for minimum JSW at both time
points. Mean and median changes in minimum JSW in both the medial and
lateral compartments are shown in Table 1.
Conclusions: These data show no signiﬁcant difference in JSW change for
naproxcinod as compared to naproxen over one year. Changes in minimum
JSW seen in this study were consistent with data reported in published
literature for patients with knee OA.
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Purpose: To determine the association between knee pain and physical
function (last 48 hours) and health related quality of life (past 4 weeks) and
prospective reporting of knee pain and global assessment of knee OA over
the following seven day period in a cohort of people with symptomatic
knee osteoarthritis participating in the two year Long-term Evaluation of
Glucosamine Sulphate (LEGS) study.
Methods: The LEGS study is a 2×2 factorial design randomised placebo-
controlled clinical trial allocating participants to glucosamine sulphate
(1500mg) and chondroitin sulphate (800mg) or matching placebo for two
years. Participants are required to attend annual clinic assessments (includ-
ing WOMAC and SF-12 questionnaires) and complete a 7-day Participant
Diary collecting daily prospective data on knee pain (At its worst, how
much pain did you have in your knee today? 0-10 (No pain to worst
pain) and a global assessment (Considering all the ways your knee arthritis
affects you, how would you say your knees are today? Excellent to Poor).
For each participant both the average knee pain score and the highest score
reported over 7 days was extrapolated for analysis. For each scale, apart
from the SF-12, higher scores indicate more pain or disability.
Results: A total of 605 people with mild to moderate symptomatic knee
OA were randomised (October 2007-2009) and completed the baseline
clinic assessment and the immediately following 7-day Participant Diary
reporting (Table 1).
Table 1. Baseline pain and disability
Clinic Assessment Mean (sd)
Age 60.3 (8.2)
Female (n,%) 339, 56%
BMI 28.9 (5.8)
Obese (n, %) 214, 35%
WOMAC pain (0-100) 33.2 (17.6)
WOMAC function (0-100) 32.4 (18.2)
SF-12 PCS 41.3 (9.5)
SF-12 MCS 52.8 (10.0)
7-day Participant Diary Mean (sd)
Left knee pain (0-100) 34.1 (18.6)
Right knee pain 33.4 (19.3)
Left highest knee pain 47.2 (20.9)
Right highest knee pain 44.9 (21.1)
• Excellent 23 (4%)
• Very good 93 (16%)
• Good 210 (36%)
• Fair 234 (41%)
• Poor 17 (3%)
The correlation between WOMAC pain and physical function scores was
unexpectedly strong (r=0.80). Unsurprisingly, there was no correlation
between the SF-12 PCS and the SF-12 MCS score (r=-0.10).
There were meaningful correlations between the WOMAC scores (past 48
hours) and prospective Participant Diary daily pain (r=0.47 to 0.54) and
global assessment of arthritis scores (r=0.45 to 0.46). There were smaller
corrections between the SF-12 PCS and the Participant Diary daily pain
scores (r=-0.31 to -0.34) and little association between the SF-12 MCS and
the Participant Diary daily pain scores (r=-0.06 to -0.11).
